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A B S T R A C T   
Nanosizing of pharmaceutical drug particles is one of the most important drug delivery platforms approaches for 
the commercial development of poorly water-soluble drug molecules. Though nanosizing of drug particles has 
been proven to greatly enhance drugs dissolution rate and apparent solubility, nanosized materials have pre-
sented significant challenges for their formulation as solid dosage forms (e.g. tablets, capsules). This is due to the 
strong Van der Waals attraction forces between dry nanoparticles leading to aggregation, cohesion, and conse-
quently poor flowability. In this review, the broad area of nanomedicines is overviewed with the primary focus 
on drug nanocrystals and the top-down and bottom-up methods used in their fabrication. The review also looks at 
how nanosuspensions of pharmaceutical drugs are generated and stabilised, followed by subsequent strategies 
for isolation of the nanoparticles. A perspective on the future outlook for drug nanocrystals is also presented.   
1. Introduction 
In the last decade, the US FDA has approved 100 nanomedicine ap-
plications and products (Etheridge et al. 2013), showing the importance 
of nanotechnology in today’s pharmaceutical and biomedical science. In 
the pharmaceutical industry, particles with sizes less than 1 µm are 
classified as nanoparticles (Dilnawaz et al. 2018). Nanotechnology plays 
a significant role in the field of medicine and drug delivery, mainly due 
to the major limitations and problems that affect conventional active 
pharmaceutical ingredients and finished dosage formulations. 
Nearly 40% of the top 200 oral drugs marketed in the USA and 
Europe, and 90% of the new chemical entities which are in the drug 
development pipelines in the pharmaceutical industry, are poorly water- 
soluble (Tan et al. 2017). Thus, the low solubility of the drug at the site 
of administration leads to a low quantity of available diffusion, leading 
to insufficient drug concentration at the site of action and in-vivo failure 
(Siepmann and Siepmann 2013). According to the Biopharmaceutical 
Classification System (BCS), pharmaceutical drugs are divided into four 
categories based on their aqueous solubility and intestinal permeability: 
namely class I (high solubility and high permeability), class II (low 
solubility and high permeability), class III (high solubility and low 
permeability) and class IV (low solubility and low permeability) (Ami-
don et al. 1995). The aqueous solubility of a drug molecule plays an 
important role in the BCS system due to its essential role in the ab-
sorption of passively transported drugs across the gastrointestinal tract 
(Devalapally et al. 2007). According to the FDA guidelines (US FDA, 
2017), a drug is considered a highly soluble drug if the highest dose 
strength of the drug can be dissolved in ≤250 mL of aqueous media at pH 
from 1 to 6.8, at a temperature of 37 ◦C ± 1 ◦C. Whereas if more than 
85% of the administered drug is absorbed in the body it is considered a 
highly permeable drug (Charalabidis et al. 2019; Rautio et al. 2008). A 
detailed description of the BCS classes is presented in Fig. 1. 
To date, the problem of low solubility has been tackled by reducing 
particle size of poorly soluble drugs using micronisation techniques 
(Aguiar et al. 2017). However, the demand for further improvements in 
drug dissolution has led to a shift from micronisation to nanonisation. In 
recent years, significant interest has developed in producing colloidal 
particles at the nanoscale with modified biological properties that allow 
modification of drug delivery and targeting. 
Depending on the composition, function, and morphology, organic 
nanoparticles can be categorised as liposomal and lipid-based, poly-
meric and core-shell, micellar, dendrimer, and drug nanocrystals, as 
presented in Fig. 2. 
Liposomes are biocompatible and can entrap hydrophilic pharma-
ceutical drugs in their internal water compartment and the hydrophobic 
pharmaceutical in the membrane. Thereby protecting the drugs from the 
inactivating effect of external conditions, without causing undesirable 
side reactions (Torchilin 2005). Liposomes are extensively studied in the 
drug delivery field due to their ability to increase the solubility and 
therapeutic index of chemotherapeutic agents (Torchilin 2005). The first 
nanomedicines approved for FDA clinical trials in the mid-1990s were 
based on the liposomal formulation of doxorubicin and amphotericin B 
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(Vaage et al. 1992). Lipid nanoparticles have proven to be life-saving 
carrier particles in the recent outbreak of coronavirus (COVID-19) 
infection by delivering mRNA to the cytosol, where it can result in 
translation of its encoded antigen (Batty et al. 2021). All pharmaceutical 
companies such as Moderna, BioNtech, and CureVac providing COVID- 
19 vaccines use lipid complexes with an mRNA encoding spike protein, 
where positively charged liposomes ionically interact with nucleotides 
to form a nanoparticle or complex (Batty et al. 2021). Moderna has 
tested mRNA lipid nanoparticles in mice to explore their immunoge-
nicity against severe acute respiratory syndrome coronavirus (SARS- 
CoV-2) (Corbett et al. 2020). Similar to Moderna, Pfizer and BioNTech 
use a proprietary nanoparticle, with BioNTech’s platform consisting of 
an ionizable lipid/phosphatidylcholine/cholesterol/PEG-lipid nano-
particle in a 50:10:38.5:1.5 M ratio (Mulligan et al. 2020). 
Polymeric nanoparticles/nanocapsules can be prepared using 
methods such as nanoprecipitation (Zili et al. 2005; Limayem Blouza 
et al. 2006), double emulsification (Jeong et al. 2008; Zhu et al. 2005), 
emulsion-diffusion (Guinebretière et al. 2002; Limayem et al. 2004), 
polymer coating (Calvo et al., 1997), emulsion coacervation (Lertsut-
thiwong et al. 2009) and layer-by-layer method (Chen et al. 2009; 
Agarwal et al. 2008). Polymeric nanomedicines are usually divided into 
two categories; (a) polymer-drug conjugate for increased half-life and 
bioavailability, and (b) controlled release application with degradable 
polymer architecture (Bobo et al. 2016). These nanocapsules are coated 
with non-ionic surfactants, which reduces immunological interactions, 
such as opsonisation. There are several examples of both FDA-approved 
polymeric nanoparticle products and those under clinical trial with 
Copaxone® being the best example. Copaxone® was initially approved 
in 1996 that acted as an immunomodulatory in the treatment of multiple 
sclerosis (Johnson et al. 1998). 
Polymeric micelles are self-assembled polymeric amphiphiles of AB 
diblock or ABA triblock copolymers in an aqueous environment tailored 
for controlled delivery of hydrophobic drugs. The use of block co-
polymers leads to lower critical micelle concentration (CMC) and 
enhanced stability in comparison to the surfactant-based micelles 
(Oerlemans et al. 2010). The hydrophobic core of the micelles is used to 
encapsulate poorly soluble drugs, thereby decreasing their elimination 
from the body, while the polar hydrophobic exterior surface allows 
dissolution in an aqueous medium (Hammad and Muller 1998). The 
core-shell structure of the micelles mimics the naturally occurring 
transport system in the body, also facilitating the absorption and dis-
tribution of entrapped drugs (Kwon and Okano 1996; Kabanov and 
Alakhov 2002). To date, estradiol (Estrasorb™) is the only FDA- 
approved micellar formulation in the market, used in the treatment of 
moderate to severe vasomotor symptoms of menopause (Bobo et al. 
2016). Furthermore, many micellar formulations are in clinical trials. 
For example, BIND-104 has presented a significant improvement in 
prostate cancer therapeutics. It is a micellar formulation made up of 
Docetaxel encapsulated in degradable and hydrophobic polymeric core 
and hydrophilic PEG shell (Hrkach et al. 2012). Other examples of 
micellar formulations currently in clinical trials are CriPec® (Rijcken 
et al. 2005) and CALAA-01 (Davis 2009). 
Dendrimers are three-dimensional, hyper-branched nanoparticles 
that terminate with several external surface functional groups (Tomalia 
et al., 1990). Due to the high solubility (Soto-Castro et al. 2012) and 
bioavailability (Duncan and Izzo 2005) of dendrimers, they are used to 
increase the solubility of a hydrophobic drug either by entrapping them 
in their intramolecular cavity or by conjugating to their external surface 
functional groups (Gupta et al. 2007; Devarakonda et al. 2005). Prios-
tar® (Swanson et al. 2007), Starburst® (Tomalia et al., 1990), Astra-
mol® (Mark 2009), and Polylysine (Patton et al. 2006) are the 
commercially available dendrimers or dendrimer-based products. 
Drug nanocrystals are another nanotechnology-based drug delivery 
platform. They are unique because they comprise 100% drug with 
improved solubility due to increased surface area leading to increased 
saturation solubility, and decreased retention in the mucosal layer. 
Nanocrystals also provide improved dose-bioavailability, reproduc-
ibility of oral absorption, and increased patient compliance via a 
reduction in the number of dosages (Müller et al. 2001; Rabinow 2005). 
Drug nanocrystals not only serve as a remarkable oral drug delivery 
system (Hanafy et al. 2007; Mauludin et al. 2009) but can also be 
injected intravenously as aqueous nanosuspensions (Rabinow 2004). 
Generally, a nanocrystal formulation contains drug nanoparticles and 
one or more stabilisers dispersed in an aqueous or non-aqueous medium. 
Fig. 1. Biopharmaceutical Classification System (BCS) characterisation of drugs based on their solubility and permeability along with measures to improve the 
pharmacokinetic properties of each class. 
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Nanocrystal-based formulation Emend® was the fastest to appear on the 
market within 10 years of the first patent filing, compared to the first 
lipid-based pharmaceutical formulation which took about 25 years to 
appear on the market (Muller et al., 1999). Drug nanoparticles can be 
produced by either top-down techniques (diminution approach), or 
bottom-up techniques (precipitation method). Both approaches will be 
discussed in this review. 
Despite several advantages of nanoparticles as mentioned earlier, 
some drawbacks include complex manufacturing (Blagden et al. 2007; 
Kipp 2004), nanotoxicity (Fischer and Chan 2007), and stability (Rabi-
now 2004; Patravale et al. 2004). Stability is one of the critical aspects of 
ensuring the safety and efficacy of drug products. Stability can be cat-
egorised as physical or chemical stability. Sedimentation, agglomera-
tion, crystal growth, and recrystallisation are generally physical stability 
issues. Whereas, degradation of functional groups such as hydrolytic 
degradation of esters and amides, and oxidative degradation of amino 
groups are chemical stability issues. Unlike the physical stability issues, 
which are commonly observed, chemical stabilities, are drug-specific. 
One example of agglomeration or crystal growth related to intrave-
nously administered nanosuspensions is the formation of larger particles 
(>5 µm) which can lead to capillary blockage and embolism (Patravale 
et al. 2004). Physical stability affects the development stages of the 
pharmaceutical product such as manufacturing, storage, and shipping. 
These physical stability issues also influence the rheological properties 
of drugs. Nanocrystals can exhibit poor flowability and compressibility 
due to their charged nature thereby driving them towards agglomera-
tion or crystal growth. This leads to an inefficient drug formulation and 
hence drug failure during the clinical stages. Hence, there is a great 
demand in the pharmaceutical sector to isolate drug nanoparticles by 
uniformly capturing/coating them onto other micron-sized carrier par-
ticles, or encapsulating them in polymer matrices, thereby, improving 
rheological behaviour in drug product. 
This article reviews the following topics related to nanoparticles: 
• Bottom-up and top-down approaches to produce dry drug nano-
particles or nanosuspensions  
• Drug nanoparticle-based products currently on the market and in 
clinical trials  
• Existing methodologies for the isolation of nanoparticles. 
2. Generation of API nanoparticles and nanosuspensions 
The pharmaceutical industry has used several particle-engineering 
technologies to control the size/size distribution, crystallinity, 
porosity, and purity of micro and nano-sized crystals. The preparation 
techniques of API nanocrystals or nanosuspensions can be broadly 
classified into three main categories, namely (1) bottom-up techniques 
involving controlled precipitation/crystallisation, (2) top-down tech-
niques involving reduction of particle size using mechanical attrition, 
and (3) combination methodologies comprising of bottom-up and top- 
down methods. The above-mentioned approaches are selected based 
on the physicochemical properties of the drugs such as solubility and 
hardness of the material (Keck and Müller 2006). 
2.1. Top-down approaches 
Top-down techniques involve high-energy approaches to reduce the 
particle size of pharmaceutical drugs down to the nanoscale. The two 
main groups of top-down approaches are media milling and high- 
pressure homogenisation (HPH), as presented in Fig. 3. Both these 
techniques are based on collisions, stress, attrition, and shearing forces 
to reduce the particle size (Lim Chin et al. 2014; Al-Kassas et al. 2017; 
Möschwitzer 2013; Gao et al. 2013). Media milling, also known as a 
mechanochemical process, includes both dry and wet media milling 
(Rasenack and Müller 2004; Merisko-Liversidge and Liversidge 2011). 
This technique was developed by Liversidge et al. in 1992 and is 
popularly known as Nanocrystal® (Möschwitzer 2013). Dry media 
milling reduces the particle size by high energy particle-particle or 
particle-wall collision under the influence of opposing high-velocity jet 
of compressed air (Louey et al. 2004). On the contrary, the wet milling 
technique uses a low energy approach in which the drug is dispersed in 
the aqueous or non-aqueous medium along with a small amount of 
stabiliser and then milled using hard glass, ceramic, or stainless steel 
balls/beads (Leleux and Williams 2014; Li et al. 2016). Milling tech-
niques have been extensively studied in the literature to reduce the 
particle size of drugs to increase their pharmacokinetic properties. Jia 
et al. produced a nanosuspension of carbendazim (an anticancer drug) 
with an average particle size of 280 ± 32 nm using Netzsch media mill at 
2000 rpm for 2 hr, with water as milling media. The relative 
Fig. 2. Illustration of different types of nanocarriers for drug delivery applications.  
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bioavailability of nanoparticle carbendazim was enhanced by 166% 
compared to regular carbendazim (Jia et al. 2003). Jinno et al. studied 
the effect of particle size on the dissolution of cilostazol (synthetic an-
tiplatelet agent with vasodilating effect) by preparing three different 
suspensions, one with a hammered mill, the second using jet milling, 
and third by forming a spray dried powder. The Nanocrystal technology 
improved the bioavailability better than the milling techniques without 
compromising the drug absorption (Jinno et al. 2006). Onoue et al. 
developed the novel respirable powder of tranilast, an antiallergic agent, 
which has been clinically used in asthma treatment, using a nanocrystal 
solid dispersion. Nanocrystals of tranilast were prepared using the wet- 
milling technique to achieve a mean particle size of 122 nm. These 
nanocrystals presented improved dissolution behaviour and lower sys-
temic concentration, thereby providing an alternative to oral therapies 
for the treatment of asthma (Onoue et al. 2011). 
High-pressure homogenisation (HPH) is the second class of the top- 
down approach. The three existing variations of HPH are as follows: 
1. IDD-P™ (insoluble drug delivery-particle) technology, micro-
fluidizer technology based on jet stream principle (Harold 1991). 
Small particles are generated by the frontal collision of two jet 
streams arranged in a Y-type or Z-type chamber under high pressure 
up to 1700 bar. Recirculation of particles between 50 and 100 times 
is needed to achieve the desired particle size.  
2. Dissocubes® technology, piston-gap homogenisation in water 
(Muller et al., 1999). Drug particles dispersed in an aqueous medium 
with some stabilisers are forced by a piston under high pressure up to 
4000 bar. This motion of aqueous suspension results in an increase in 
Fig. 3. Top-down and Bottom-up approaches used to generate API nanosuspensions or dry nanoparticles (Padrela et al. 2018).  
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dynamic pressure which is compensated by a reduction in the static 
pressure below the vapour pressure of the aqueous phase leading to 
the boiling of water. This creates gas bubbles that implode upon 
leaving the homogenisation gap. The high-energy shock wave 
generated from the cavitation process breaks the drug particles 
(Shegokar and Müller 2010).  
3. Nanopure® technology, piston-gap homogenisation in reduced 
water, or non-aqueous media (Helmut et al., 2000). This is an 
advanced version of the Dissocubes® technology using a non- 
aqueous medium with homogenisation happening at room temper-
ature. Size diminution occurs due to shear force, particle collisions, 
and turbulences (Shegokar and Müller 2010). 
Top-down techniques mostly use water as a non-solvent to disperse 
poorly soluble drugs, making these techniques more eco-friendly. In 
general, because of the more streamlined process flow, controlled par-
ticle size, and the non-solvent feature of top-down methods, most of the 
marketed and developmental nanosuspension-based pharmaceutical 
formulations have been produced by top-down methods. 
Hanafy et al. enhanced the bioavailability of poorly soluble fenofi-
brate by forming its nanosuspension using DissoCube and comparing it 
with three other formulations, one solid lipid nanoparticle and two 
suspensions of micronized fenofibrate (Hanafy et al. 2007). Ganta et al. 
prepared dry nanoparticles (133 ± 22 nm) of Asulacrine using HPH 
techniques followed by freeze drying that improved physical and 
chemical stability. The nanosuspension of asulacrine nanoparticles 
presented a lower plasma concentration compared to its solution state 
which increases its half-life to 6 h from 2.7 h (Ganta et al. 2009). Mitri 
et al. prepared a nanosuspension of Lutein using the HPH approach with 
a particle size of 429 nm presenting a 26.3 fold increase in the saturation 
solubility compared to the coarse powder. In-vitro permeation through a 
cellulose nitrate barrier also increased 14-fold (Mitri et al. 2011). 
2.2. Bottom-up approaches 
Typically in bottom-up approaches, nanoparticles of a drug are 
precipitated in crystalline or amorphous form from a supersaturated 
solution (aqueous/organic) (Al-Kassas et al. 2017), by evaporation of 
solvent or by use of an antisolvent (Sinha et al. 2013; Salazar et al. 
2012). The bottom-up approach is broadly classified into two categories 
namely, precipitation methods and evaporation methods, as shown in 
Fig. 3. The liquid antisolvent precipitation method is the most effective 
method to produce drug nanoparticles. Mixing of drugs, previously 
dissolved in a solvent, with an antisolvent (e.g. water) results in 
increased supersaturation leading to the formation of a large number of 
small particles. This is an easy, cost-effective, and scalable process 
compared to other methods of nanosizing. This technique has been 
widely used in the literature to produce nanoparticles of fenofibrate 
(Tierney et al. 2017), mefenamic acid (Bodnár et al. 2017), valsartan 
(Kumar et al. 2019), atorvastatin (Zhang et al. 2009), taxifolin (Zu et al., 
2014b), donazol (Zhao et al. 2009), dalcetrapib (Bodnár et al. 2020), 
and amorphous amphotericin B (Zu et al., 2014a). 
Sonoprecipitation is another approach to produce uniformly 
dispersed nanoparticles working on the cavitation principle. The size of 
the final product depends on the ultrasound frequency, duration, in-
tensity, and horn length. Amorphous nanoparticles of cefuroxime axetil 
were produced using this technique with a particle size of 130 nm which 
further decreased to 80 nm on doubling the amplitude of sonication 
(Dhumal et al. 2008). Another bottom-up nanosizing approach is high 
gravity antisolvent precipitation, where the drug dissolved in a solvent is 
mixed with antisolvent in a rotating packed bed chamber. The mixture is 
subjected to high gravity due to centrifugal force allowing the mixture to 
pass through the packing thereby leading to the formation of uniform 
size nanoparticles (Sinha et al. 2013). Nanoparticles of cefuroxime axetil 
with a particle size of 300 nm were produced without any stabiliser, and 
with a four-fold increase in surface area compared to the commercial 
formulation (Chen et al. 2006). 
The use of supercritical CO2 is another approach to reduce the par-
ticle size of drugs. Dissolving drugs in supercritical CO2 and then 
expanding the solution into a low-pressure area using a narrow nozzle 
orifice of <100 µm results in the formation of nanosized drug particles. 
This process is known as the rapid expansion of supercritical solutions 
(RESS) (Padrela et al. 2018; Matson et al. 1986; Matson et al. 1987). 
Nanoparticles of raloxifene (19 nm) (Keshavarz et al. 2012), theophyl-
line (85 nm) (Uchida et al. 2015), magestrol acetate (102–516 nm) 
(Samei et al. 2012), naproxen (560–820 nm) (Türk and Bolten 2010), 
and phenytoin (75–120 nm) (Thakur and Gupta 2006) have been suc-
cessfully produced using RESS and its derivative approaches. Additional 
supercritical CO2-based processes include the supercritical antisolvent 
(SAS) and the Gas antisolvent (GAS) processes, which use supercritical 
CO2 as an antisolvent, with the drug previously dissolved in a solvent 
(Padrela et al. 2018; Rodrigues et al. 2009; Rodrigues et al. 2011; 
Padrela et al. 2017). The particle size of the precipitated drug depends 
on the solvent/antisolvent ratio, drug concentration, degree of mixing 
and rate of antisolvent addition (Reverchon 1999; Reverchon et al. 
2007). In addition, supercritical assisted spray drying (SASD) process 
have also been successfully used both to generate nanoparticles and 
control the polymorphic form of carbamazepine, risperidone, ketopro-
fen (Verma et al. 2020; Long et al., 2019a, 2019b), and carbamazepine- 
saccharin cocrystal (Padrela et al. 2019). 
Spray drying is a well-known evaporative method to produce micro- 
particles of pharmaceutical drugs. The nanospray drying method, Buchi 
B-90, was developed by Buchi Labortechnik AG, Switzerland to produce 
nanoparticles of pharmaceutical drugs (Bürki et al. 2011) (Heng et al. 
2011). The working principle of the nanospray dryer is thoroughly 
explained by Kassas et al. (Al-Kassas et al. 2017). Nanoparticles of vil-
dagliptin (445 nm) (Harsha et al. 2015) and calpain inhibitor (300 nm) 
(Baba and Nishida 2012) have been successfully produced using the 
nanospray dryer. Onoue et al. developed a respirable powder formula-
tion of cyclosporine A using spray dried O/W emulsion. A mixture of 
erythritol and O/W emulsion of cyclosporine A, polyvinylpyrrolidone, 
and glyceryl monooleate (an emulsifier) was spray dried and mixed with 
the lactose carrier. The nanoemulsified particles generated with a mean 
diameter of 317 nm, exhibited a 4500 fold increase in the dissolution 
rate of cyclosporine A (Onoue et al. 2012). Another evaporative method 
to produce nanoparticles is spray freeze drying, where the drug solution 
is atomised into the cryogenic liquid resulting in the freezing of formed 
particles which are later lyophilised. This process generally produces 
amorphous nanoparticles with high surface area (Singh and Van den 
Mooter 2016). Hu et al. produced 100 nm amorphous particles of da-
nazol using a spray freezing approach which exhibited high surface area 
and solubility (Hu et al. 2004). 
Nanoparticles below 100 nm have proven to possess novel physical 
properties and improved permeation through various biological bar-
riers, although this size range has proven difficult to form by either top- 
down or bottom-up methods (Sinha et al. 2013). Therefore, to enhance 
the efficacy of both the approaches and to achieve ultrafine nano-
particles, combination approaches are being studied. Combination 
techniques involve a pre-treatment step involving bottom-up techniques 
followed by a high-energy top-down technique (Möschwitzer 2013). 
Nanoedge® by Baxter Inc. was the first reported combination technique 
involving antisolvent precipitation generating amorphous micro- 
particles that are later converted to crystalline nanoparticles using 
high-pressure homogenisation (Kipp James et al. 2001). Xu et al. re-
ported producing ultrafine particles of beclomethasone dipropionate for 
dry powder inhalation using this process (Xu et al. 2012). This approach 
was also used to prepare nanosuspensions of itraconazole and isradipine 
with a mean particle size below 500 nm (Shelar et al. 2013; Rabinow 
et al. 2007). The SmartCrystal® platform of techniques commercialised 
by Abbott labs includes combination technologies such as H42 (spray 
drying followed by HPH), H69 (flow precipitation followed by HPH), 
H96 (lyophilisation followed by HPH) (Salazar et al. 2014). A detailed 
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description of all the combination technologies is discussed by Salazar 
et al. in their review article (Salazar et al. 2014). 
3. API nanoparticle-based drugs in the market 
The global nanomedicine market is anticipated to reach USD 350.8 
billion by 2025, according to a new report by Grand View Research, Inc. 
(“Nanomedicine Market Size Worth $350.8 Billion By 2025 | CAGR: 
11.2% (Available at: https://www.grandviewresearch.com/press- 
release/global-nanomedicine-market)” 2017) The key players operating 
in this industry include Pfizer Inc., Ablynx NV, Nanotherapeutics Inc., 
Nanoviricides Inc., Abraxis Inc., Arrowhead Research Inc., Celgene 
Corporation, Bio-Gate AG, and Merck. Doxil® was the first FDA- 
approved liposome-based nano-drug (1995), which was administered 
intravenously (Barenholz 2012). Since then the FDA has approved more 
than 50 nano drugs mostly based on liposomes, polymers, and nano-
crystals for various therapeutics (Caster et al. 2017; Bobo et al. 2016). 
Whereas, Rapamune® was the first nanocrystal-based FDA-approved 
drug by Wyeth in 2000. The 370 mg tablet contains only 1–3 mg of 
sirolimus. The low drug loading eliminated the tablet compression 
problem such as nanocrystal agglomeration, which is a common feature 
of nanocrystal products. Also, the bioavailability of the nanocrystal 
tablet was 21% higher than that of the nanosuspensions, showing that 
the kinetic saturation solubility is greater than the saturated solubility in 
solution (Shegokar and Müller 2010). Rapamune provided a constantly 
extended-release profile to the poorly soluble drug that helped to pre-
vent organ rejection following transplantation. Rapamune nano-
formulation was prepared by coating sirolimus nanosuspension onto 
inert tablets cores, which consists of lactose monohydrate, macrogel, 
and talc. Other nanocrystal based products in the market are Megace® 
ES (megestrol acetate), Avinza® (morphine sulfate), Ritalin LA® 
(methylphenidate HCl), Zanaflex® (tizanidine HCl), Herbesser® (dilti-
azem), Emend® (aprepitant), TriCor® (fenofibrate), Triglide® (fenofi-
brate), Focalin XR® (dexmethylphenidate HCl), Cesamet® (nabilone), 
Naprelan® (naproxen sodium), Invega® (paliperidone), Invega® Sus-
tenna® (paliperidone palmitate), Ryanodex® (dantrolene sodium), 
Zorvolex® (Diclofenac), and Invega® Trinza® (paliperidone palmitate). 
These are presented in Table 1 along with their active ingredient, dosage 
form, developer, and FDA approval date. Among all the marketed 
nanoformulations only four are administered as nanosuspensions while 
others are as tablets or capsules. Within this group of nanomedicines, 
Invega® Sustenna® generated the maximum revenue of $1.8B in the 
year 2015 making it the most successful nanocrystal-based formulation 
(Havel 2016). Most of these formulations are manufactured using the 
nano-milling technology pioneered by Elan (now Alkermes), generating 
nanocrystals of less than 400 nm in size which was stabilised success-
fully to pass the FDA regulations (Liversidge et al. 1992). 
Several nanocrystal-based drugs are currently in clinical trials, as 
presented in Table 2. All these drugs are poorly soluble and have min-
imal bioavailability. Semapimod® (guanylhydrazone) acts as an 
immunomodulator, preventing the reduction of TNF-α (a pro- 
inflammatory cytokine) during Phase I study in cancer patients. Pax-
ceed® (paclitaxel), an anti-inflammatory that could potentially reduce 
hypersensitivity in cancer-treated patients. Theralux (temactacin) can 
be potentially used to treat autoimmune diseases and cancer. Pan-
zemNCD (2-methoxy estradiol) has shown promising antiproliferative 
and antiangiogenic properties in clinical trials (Jarvis et al. 2019), but 
did not proceed beyond Phase II and all its clinical developments were 
suspended due to its clinically insignificant study in treating prostate 
cancer (Harrison et al. 2011). A recent review by Anselmo and Mitra-
gotri, reviews the current landscape of nanoparticle drug delivery sys-
tems and provides an update on the various types of nanomedicines in 
clinical trials (Anselmo and Mitragotri 2019). 
4. Why there is a need to capture drug nanoparticles? 
Despite the benefits of nanoparticles and the relative ease of 
administration, nanoparticles provide special challenges in the design of 
nanosuspension formulations, as well as nano-powder formulations. 
Though nanoparticles exhibit a characteristic nonlinear increase in ki-
netic solubility upon nanosizing as described by the Ostwald-Freundlich 





) (1)  
Where SNP is the solubility of nanoparticles with radius r, S0 is the sol-
ubility of bulk material, Vm is the molar volume, γ is the interfacial 
tension, R is the gas constant and T is the temperature. The effect of 
particle size on drug dissolution increases exponentially by changing the 
particle size from 1 µm to 100 nm. The increased dissolution is advan-
tageous for non-targeted delivery of oral drugs but it becomes a draw-
back for intravenous delivery of nanosuspensions. The enhanced 
solubility at the non-targeted site for a targeted delivery system reduces 
its efficacy as a drug due to the reduced circulation time of the nano-
systems. This further reduced the efficacy and utilisation of stabilising 
Table 1 
Key characteristics of commercially available drug products based on engineered nanoparticle technology. Modified from (Bobo et al. 2016; Shegokar and Müller 
2010).  
Active ingredient Trade name Dosage form Technology Developer Approved date (FDA) 
Griseofulvin Gris-Peg® Tablet Coprecipitation Novartis 1982 
Sirolimus Rapamune® Tablet Wyeth 2000 
Nabilone Cesamet® Tablet Lilly 2005 
Veraapamil Verelan PM® Tablet Media milling Schwarz Pharma 1998 
Megestrol acetate Megace® ES Nano suspension Par Pharm 2001 
Morphine sulfate Avinza® Capsule Pfizer 2002 
Methyl phenidate HCl Ritalin LA® Capsule Novartis 2002 
Tizanidine HCl Zanaflex® Tablet Acorda 2002 
Diltiazem Herbesser® Tablet Mitsubishi Tanabe Pharma 2002 
Aprepitant Emend® Capsule Merck 2003 
Fenofibrate TriCor® Tablet Lupin Atlantis 2004 
Dexmethyl phenidate HCl Focalin XR® Tablet/ Capsule Novartis 2005 
Naproxen sodium Naprelan® Tablet Wyeth 2006 
Theophylline Theodur® Tablet Mitsubishi Tanabe Pharma 2008 
Paliperidone Invega® Tablet Janssen Pharmaceuticals 2009 
Diclofenac Zorvolex® Capsule Iroko Pharmaceuticals 2016 
Fenofibrate Triglide® Tablet High pressure homogenisation SkyePharma 2005 
Paliperidone Palmitate Invega® Sustenna® Nano suspension Janssen Pharmaceuticals 2014 
Paliperidone Palmitate Invega® Trinza® Nano suspension Janssen Pharmaceuticals 2015 
Dantrolene Sodium Ryanodex® Nano suspension – Eagle Pharmaceuticals 2014  
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and/or targeting agents (Peltonen and Hirvonen 2018). Shegokar et al. 
provided evidence of an increase in bioavailability of nanoparticles of 
sirolimus by 21% compared to that of the nanosuspension of the same, 
presenting that the kinetic saturation solubility is greater than the 
saturated solubility in solution (Shegokar and Müller 2010). Further-
more, the stabiliser used to stabilise the nanosuspension could also lead 
to toxicity. 
The market for oral administration is enormous and, since the 
product is primarily composed of the drug and can be incorporated with 
GRAS-approved stabilizers and excipients, the regulatory approval 
process for nanocrystal drug products is easier (Jarvis et al. 2019). The 
special challenge with nanocrystals is the design of oral solid drug for-
mulations. The strong Van der Waals attraction force between the dry 
nanoparticles leads to aggregation, cohesion, and consequently poor 
flowability. Hence, to improve the stability, handling, and flowability of 
powder formulations, APIs micro/nano particles are often combined 
with large carrier/excipient particles. However, drug content uniformity 
and further aggregation in downstream processing steps remain a 
concern (Han et al. 2013). Nanocrystal agglomeration remains a 
bottleneck issue in the pharmaceutical industry and because of this, 
nanocrystal formulations struggle to reach clinical trial stages. There-
fore, the isolation of these nanocrystals is the prime focus in the phar-
maceutical community, to enhance the stability of nanocrystals in future 
medicines. 
5. Isolation methodologies of drug nanoparticles 
Most of the nanoparticle isolation methodologies converge to either 
the coating of carrier particles (host) with the drug nanoparticles (guest) 
or encapsulation of drug nanoparticles (guest) with the carrier particles 
(host). This host-guest interaction presents a feasible way to immobilise 
nanoparticles on a larger surface. This improves material handling 
throughout the manufacturing line and further facilitates the delivery of 
formulation to the patient (Matos et al. 2020). The coating of nano-
particles onto carrier particles could be discrete or continuous depend-
ing on the experimental requirements. The discrete coating is produced 
when the nanoparticles attach in small pockets onto the surface of the 
carrier particle. While the continuous coating is produced as a mono-
layer on the surface of carrier particles. Moreover, a continuous coating 
is preferred as it produces content homogeneity in the batch. This uni-
form coating mostly depends on two factors, surface charge and drug 
loading, which are interrelated. Similarly, encapsulation also aims to 
capture individual drug nanoparticles, which are subsequently coated 
by carrier particles. 
Different technologies have been used to either coat a carrier with 
nanoparticles or to encapsulate nanoparticles in a carrier matrix. For 
coating, carriers can be either microparticles like excipients or solid 
forms as metallic medical devices. Advantages of coating/encapsulating 
nanoparticles onto/by the carrier particle are as follows:  
• Operation at a lower temperature compared to hot melt extrusion, 
and hence with thermally labile core and coating material.  
• Using organic solvent in the processing of APIs without risk of 
explosion.  
• Coating onto water-soluble API at near ambient temperatures 
without the risk of API degradation. 
Nanoparticle isolation processes can be further subdivided based on 
the number of steps required. The generation of dry nanoparticles and 
isolating them in the same step with a coupled technology is a single- 
step process. While the generation of nanosuspensions and then drying 
these into nanoparticles coupled with isolation, the technique is a multi- 
step process. Fig. 4 presents the different isolation techniques involved 
in single-step and multi-step isolation processes of encapsulation and 
coating. 
5.1. Single-step nanoparticle isolation processes 
In single-step nanoparticle isolation processes, the API solution is 
converted into nanoparticles which are isolated by either encapsulation 
or coating in the same step. Broadly it involves three techniques namely, 
supercritical CO2 processing, nanospray drying, and electrospraying. 
5.1.1. Supercritical CO2 processes 
5.1.1.1. Encapsulation of drug nanoparticles using supercritical CO2 proc-
esses. Various supercritical CO2 processes have been used to isolate 
nanoparticles in the past either by encapsulation or by coating ap-
proaches, as presented in Fig. 5. In 2000, Benoit et al. (Benoit et al. 2000) 
developed a supercritical fluid technique that assisted the API encap-
sulation process, where API microparticles are encapsulated with lipids 
or polymers. Niu et al. (Niu et al. 2012) reported the encapsulation 
approach to encapsulate caffeine-loaded microcrystalline cellulose 
(MCC, 1–1.4 mm) beads with ethyl cellulose using the Supercritical 
Antisolvent process integrated with Wurster type coater (SAS-WTS). 
This resulted in the delayed release of the caffeine from MCC beads, 
demonstrating the ability of the process to prepare controlled-release 
formulations. Another similar process, Supercritical Antisolvent Pre-
cipitation with Enhanced Mass transfer (SAS-EM) was used to form 
PLGA-curcumin nano-capsules with an average size of 63 nm and the 
drug loading of 38%. The average size of the nano-capsules could be 
further decreased to 40 nm, while the drug loading was reduced to 36%, 
by increasing the ultrasonic power from 210 W to 350 W (Zabihi et al. 
2014). To increase the loading efficiency, the Suspension-Enhanced 
Dispersion by Supercritical Fluid (SpEDS) process was used to prepare 
microencapsulation of methotrexate and Fe3O4 by spraying Fe3O4 sus-
pended in an organic solution of methotrexate. These microcapsules 
were further suspended in a PLLA-PLG-PLLA polymeric solution, which 
was sprayed again into scCO2 (supercritical CO2) generating a second 
layer of microencapsulation. This process increased the loading up to 
8.9 wt% and loading efficiency up to 60.8% (Chen et al. 2012). The 
limitation of this encapsulation process is the ability of supercritical 
fluid to dissolve the encapsulating material but not the API particles. 
5.1.1.2. Coating of drug nanoparticles using supercritical CO2 processes. 
The combination of fluidised bed coating and supercritical fluid-based 
precipitation has been reported for many years. These techniques are 
schematically presented in Fig. 5. Tsutsumi et al. (Tsutsumi et al. 1995) 
coated paraffin nanoparticles (500 nm) precipitated using Rapid 
Expansion of Supercritical Solvents (RESS) onto the surface of micro-
spheroidal catalyst particles (56 µm) in a circulating fluidised bed pro-
cess. Subramaniam et al. (Subramaniam et al. 1998) demonstrated the 
use of fluidised bed technology to coat micron-sized carrier particles 
with nano/micron-sized drug particles. In this method, a dense CO2 is 
Table 2 
Nanocrystal drug products in clinical trials. Modified from (Jarvis, Krishnan, and Mitragotri 2019).  
Active ingredient Trade name Dosage form Developer Clinical status 
Guanylhydrazone Semapimod® Nanosuspension Cytokine Pharmasciences II 
Paclitaxel Paxceed® Nanosuspension Angiotech III 
Temectacin Theralux Nanosuspension Celmed II 
2-methoxy estradiol PanzemNCD Tablet EntreMed II  
V. Verma et al.                                                                                                                                                                                                                                  
International Journal of Pharmaceutics 603 (2021) 120708
8
used to fluidise the carrier particles while the drug dissolved in a solvent 
is sprayed with the help of this dense CO2 onto the fluidised carrier 
particles. The dense CO2 also acts as a drying gas for the nano/micro 
particles by selectively extracting the solvent. Integration of supercriti-
cal CO2 process with the fluidised bed process to capture the spray dried 
API particles onto carrier particles, reduced the product transferability 
between processes and lowers the risk of operator’s exposure to the drug 
nanoparticles. Further to avoid drug-drug particle agglomeration, 
Sathigari et al. also used the supercritical antisolvent-drug excipient 
mixing (SAS-DEM) process to precipitate micro-particles of itraconazole 
(0.73–1.73 µm, 6–50 wt% loading) in the presence of surfactants (so-
dium dodecyl sulfate and poloxamer 407) and successfully coated them 
onto lactose powder (~100 µm) (Sathigari et al. 2011). Hence, this 
confirms that the supercritical CO2 process is an efficient way to coat 
drug nanoparticles onto micron-sized carrier/excipient particles. 
Furthermore, improvement in drug release suggested a reduction in 
particle-to-particle agglomeration. 
In 2014, Leeke et al. (Leeke et al. 2014) used the ability of sc-CO2 to 
act as a solvent by adapting the Rapid Expansion of Supercritical Solu-
tions (RESS) process in combination with the Wurster coater (RESS- 
WTS) and the fluidised bed (RESS-BFB). In both processes, the jet of sc- 
CO2 saturated with the API is expanded in an upward direction in a bed 
of excipient particles. Table 3 presents different supercritical CO2 pro-
cesses that are coupled with a fluidised bed system to coat API nano-
particles onto carrier particles. Nanoparticles (<30 nm) of vitamin K3, 
benzoic acid, and other organic compounds were precipitated onto 
microcrystalline (MCC, 300 µm), close to the point of generation of 
nanoparticles, thereby avoiding particle agglomeration. A uniform layer 
of API nanoparticles was formed onto the surface of MCC particles 
without compromising MCC flowability. Though the processing yield 
was between 14 and 74%, the API loading was poor (0.01–0.54 wt%) 
due to the poor solubility of API in sc-CO2 making this process less 
feasible to be adapted in the pharmaceutical industry. 
Considering the limitation of sc-CO2 to freely dissolve APIs, the same 
group used Supercritical Antisolvent (SAS) process integrated with a 
fluidised bed (SAS-FB) to coat API nanoparticles onto carrier particles in 
a single step. Nanoparticles of naringin (<200 nm) were precipitated 
onto MCC particles (100–500 µm) with a drug loading of 2.5 wt%. The 
faster dissolution rate of naringin was obtained when compared to the 
dissolution rate of naringin precipitated using a conventional fluidised 
bed process (Li et al. 2017). A similar approach was used by Matos et al. 
(Matos et al. 2018; Matos et al. 2020) to precipitate curcumin nano-
particles onto α-lactose monohydrate (125–145 µm), MCC (175 µm), 
corn starch (15 µm), and lactose (5 µm). The drug yield was between 71 
and 93% and the drug loading was between 1 and 6 wt%. Due to effi-
cient mixing in the SAS-FB process, smaller and less aggregated nano-
particles of curcumin were precipitated compared to the particles 
obtained from the SAS process. To achieve uniform coatings using a 
fluidised bed process integrated with the sc-CO2 process, the CO2 flow 
rate should be high enough to efficiently fluidise all the carrier particles. 
5.1.1.3. Supercritical CO2-assisted dynamic bed coating process. The 
Fig. 4. Single-step and multi-step nanoparticle production and isolation methodologies. RESS (Rapid Expansion of Supercritical Solutions), SAS (Supercritical 
antisolvent), SAS-WTS (Supercritical antisolvent process integrated with Wurster type coater), SAS-EM (Supercritical Antisolvent Precipitation with Enhanced Mass 
transfer), SpEDS (Suspension-Enhanced Dispersion by Supercritical Fluid), SAS-DEM (Supercritical antisolvent – Drug Excipient Mixing), RESS-WTS (Rapid 
Expansion of Supercritical Solutions process in combination with the Wurster coater), RESS-BFB (Rapid Expansion of Supercritical Solutions process in combination 
with the Fluidised Bed), SAS-FB (Supercritical Antisolvent Precipitation with Fluidised Bed). 
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supercritical CO2 process such as supercritical antisolvent (SAS) has 
been used in combination with fluidized bed technology to coat micron- 
sized carrier particles with drug nanoparticles (Li et al. 2017). Different 
experimental approaches involve spraying of organic solute onto flui-
dised carrier particles, resulting in the low loading of < 4% and poor 
processing yield. (Li et al. 2017; Leeke et al. 2014). Recently, Verma 
et al. (Verma et al. 2020) reported a novel production and isolation 
method for drug nanoparticles using a ‘top spray dynamic bed coating’ 
process (as shown in Fig. 6), which uses CO2 spray as the fluidizing gas. 
Nanoparticles of poorly soluble APIs such as carbamazepine, ketoprofen, 
and risperidone were produced and captured onto micron-sized micro-
crystalline cellulose carrier particles that were located on the top of the 
steel mesh inside the drying chamber, thereby improving the rheological 
properties of poorly soluble drug nanoparticles. The size distribution of 
the API nanoparticles was in the range of 90–490 nm, while a variable 
API loading of 10% to 20% was successfully achieved. Further, disso-
lution of risperidone was enhanced by 6-times compared to as-received 
risperidone particles, while the dissolution of ketoprofen and carba-
mazepine was increased 3-fold and 2-fold, respectively. 
5.1.2. Nanospray drying equipped with electrostatic collector 
Conventional spray drying has long been a useful technique to con-
trol the size and morphology of micron-sized particles of pharmaceutical 
drugs. However, the increased efficacy of nanoparticles compared to 
microparticles, increased the need to extend the capabilities of existing 
spray dryers into the nanometer regime (Heng et al. 2011; Al-Kassas 
et al. 2017; Baba and Nishida 2012). Buchi Labortechnik has devel-
oped the Nano spray dryer B-90 (shown in Fig. 7) to deliver particle sizes 
within the range of 300 nm to 5 µm, for milligram sample quantities at 
high yield, with minimal activity loss (Heng et al. 2011). The spray 
drying process is generally divided into three major phases: atomisation, 
solvent evaporation, and particle collection. Briefly, ultra-fine droplets 
are produced using vibration technology. The piezoelectric actuator is 
driven at an ultrasonic frequency of 60 kHz resulting in the vibration of 
the steel membrane (4–7 µm), thus ejecting ultra-fine droplets. These 
droplets dry to form nanoparticles while traversing through the drying 
chamber with the inert carrier gas. The drying gas escapes from the 
bottom of the chamber. Dried nanoparticles are collected using elec-
trostatic precipitators, as they have the advantage to collect lower size 
particles especially 50 nm. The cyclone used in the conventional spray 
dryers is unable to collect small particles less than 2 µm efficiently (Heng 
et al. 2011). The organic solvents used to dissolve poorly water-soluble 
drugs are mainly ethanol, methanol, acetone, ethyl acetate, and 
dichloromethane. With highly diluted solutions containing 0.1–1% (w/ 
Fig. 5. Schematic of drug nanoparticle isolation using supercritical CO2 coating and encapsulation processes. SAS-WTS is Supercritical Antisolvent process integrated 
with Wurster type coater, SAS-EM is Supercritical Antisolvent Precipitation with Enhanced Mass transfer, SpEDS is Suspension-Enhanced Dispersion by Supercritical 
Fluid, RESS-BFB is Rapid Expansion of Supercritical Solutions integrated with Fluidised bed, RESS-WTS is Rapid Expansion of Supercritical Solutions integrated with 
Wurster type coater, SAS-FB is Supercritical Antisolvent process integrated with Fluideised bed, and SAS-DEM is Supercritical Antisolvent-Drug Excipient Mixing. 
Table 3 
Supercritical CO2 processes that are coupled with a fluidised bed system to 
isolate pharmaceutical nanoparticles by coating onto carrier particles in a single- 
step process.  




Curcumin α-lactose monohydrate 
(125–145 µm) 





Curcumin Microcrystalline cellulose 
(175 µm)Corn starch  
(15 µm)Lactose  
(5 µm) 





Naringin Microcrystalline cellulose 
(100–200 µm, 200–355 µm, 
& 355–500 µm) 
(Li et al. 
2017) 








(Leeke et al. 
2014)  
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v) solid concentrations, fine solid particles down to 50 nm can be ob-
tained by nanospray drying. Comprehensive use of the nanospray dryer 
is well reported in the literature (Arpagaus et al. 2017; Arpagaus et al. 
2018). 
The nanoparticles produced tend to agglomerate upon isolation 
hence some researchers used polymers to encapsulate these drug 
nanoparticles. Table 4 presents a summary of the APIs isolated from the 
solution using the nanospray dryer. Recently, Harsha et al. (Harsha et al. 
2015) prepared nanospheres (445 nm) of vildagliptin with aminated 
gelatin using the Buchi nano spray dryer B-90. The drug content and 
percentage yield of the nanospheres were found to be 76.2 ± 4.6% and 
83 ± 2%, respectively. The nanospheres also presented good flowability 
as the angle of response value was 33.5◦ (cut-off is 40◦). The same 
research group also prepared amoxicillin-loaded carbopol nanospheres 
with particle size in the range of 280–320 nm for the controlled release 
of amoxicillin. The drug content and percentage yield were 85.3% ±
0.7% and 92.8% ± 0.9%, respectively. Nanospheres allowed a 19% 
dissolution in 30 min compared to the 90% dissolution of amoxicillin 
nanosuspension. The nanospheres enabled the controlled release of 
amoxicillin over an extended period of 12 h (Harsha 2012). Harsha et al. 
also prepared vildagliptin-loaded carbopol nanospheres (355.8 nm) to 
provide a sustainable release for a prolonged time. The nanosphere also 
presented good flowability as the angle of repose was <32.4◦ (Sree 
Harsha et al. 2013). Sithole et al. (Sithole et al. 2018) prepared the 
acyclovir-loaded semi-synthetic biopolymer complex (SSBC) nano-
particles with an average particle size of 257.92 nm. The SSBC nano-
particles improved the solubility of acyclovir by 30% and the ex-vivo 
permeation by 10% compared to the conventional acyclovir formula-
tions, thereby improving its bioavailability. The nanoparticles generated 
displayed either amorphous or semi-crystalline phases. Recently, 
Baghdan et al. (Baghdan et al. 2018) used the nanospray dryer B-90 to 
coat medical implants with curcumin nanoparticles to improve the 
biocompatibility of the implant as well as avoid tissue generation on the 
implant. The average particle size of the coated nanoparticles was 500 
Fig. 6. Schematic representation of (A) top spray dynamic bed coating process, (B) enlarged view of the drying chamber consisting of a co-axial nozzle at the top, 
carrier particle holder in the middle, and CO2 outlet at the bottom part of the chamber. (). 
Adapted from Verma, Ryan, and Padrela 2020 
Fig. 7. Schematic of the nanospray dryer (Buchi B-90) that uses an electric field 
to isolate encapsulated drug nanoparticles. 
Table 4 
A summary of API nanocrystals isolated from solution using nanospray drying 
technique.  
API Excipient Nanoparticle 
size 
Yield Reference 




Vildagliptin Carbopol-934P 355.8 nm 96 ±
0.4% 
(Sree Harsha 
et al. 2013) 





257.92 nm 85% (Sithole et al. 
2018) 
Curcumin Medical Implant 500 nm – (Baghdan 
et al. 2018)  
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nm. Another advantage of this process is the isolation of nanoparticles 
by the coating process without the need for additives to stabilise the 
nanoparticles. 
5.1.3. Electrospraying to encapsulate and isolate drug nanoparticles 
Electrohydrodynamic atomisation (EHDA) is a process to convert 
liquid jets breaks up into fine droplets under the influence of an external 
electric field, as shown in Fig. 8. EHDA is classified into electrospinning 
and electrospraying. In the electrospraying process, a conical-shaped 
‘Taylor cone’ is formed at the tip of the needle due to two electrostatic 
forces namely electrostatic repulsion of induced like charges in the 
liquid and columbic force of external electric field liquid droplets. A fine 
jet of the charged polymeric solution is broken into fine droplets which 
move towards the collector to overcome the surface tension of the liquid. 
The solvent gets evaporated forming solid particles during the flight 
path between the tip and the collector (Anu Bhushani and Anandhar-
amakrishnan 2014). Generally, low solution concentrations are used for 
the electrospraying process. Droplet size is further influenced by con-
ductivity, surface tension, viscosity of the solution, and flow rate (Chen 
et al. 1995; Xie et al. 2006; Jaworek 2007). A detailed overview of the 
electrospraying process and the influence of the process parameter on 
the droplet formation is well documented in the literature (Peltonen 
et al. 2010; Pawar et al. 2018). 
Electrospraying is a potential method for producing polymeric 
nanoparticles and for encapsulating both hydrophilic and hydrophobic 
drugs efficiently in them. Table 5 summarises the API nanocrystals 
isolated from solutions using the electrospraying technique. Xie et al. 
(Xie et al. 2006) produced paclitaxel-poly(D, L-lactide-co-glycolide) 
(PLGA) nanoparticles with an average particle size of 250 nm. Similarly, 
polylactide (PLA) was used to produce polymeric nanoparticles of 
beclometasone dipropionate and salbutamol sulfate with an average 
nanoparticle size of 200 nm (Valo et al. 2009). In a related study, Arya 
et al. (Arya et al. 2009) optimised the electrospraying process parame-
ters to produce ampicillin-loaded chitosan nanospheres with an average 
particle size of 520 nm and encapsulation efficiency of 80.4%. The drug- 
loaded nanospheres showed an initial burst release followed by a sus-
tained release for 5 days, thereby making these particles the most suit-
able for sustained nasal and gastrointestinal tract delivery. A different 
approach by Wu et al. (Wu et al. 2009) was used as an electrospray to 
construct bioresponsive peptide-based particulates (300–400 nm) 
encapsulating doxorubicin using genetically engineered elastin-like 
polypeptides (ELPs). Therefore, electrospraying is an efficient and 
flexible method for generating stimuli-responsive drug particles. Elec-
trospraying has also been used to generate spherical nanoparticles 
(average particle size of 400 nm) of an anti-bacterial drug, curcumin, 
encapsulated in gelatin. Curcumin-loaded gelatin nano-spheres showed 
improved anti-bacterial properties (25-fold) compared to raw curcumin 
(Gómez-Estaca et al. 2017). Further, electrospraying can also be used to 
produce core-shell nanoparticles (280–450 nm) for sustained release 
applications by loading the drug into a pH-sensitive polymer, thereby 
reducing the side effects and improving the therapeutic effect of the drug 
(Hao et al. 2014). In a similar study, Cui et al. (Cui et al. 2014) suc-
cessfully prepared core-shell nanoparticles (average diameter of 530 ±
80 nm) of polyvinylpyrolidone (PVP) and shellac with ferulic acid for 
controlled release formulation. Recently, Garjani et al. (Garjani et al. 
2018) were able to produce nanobeads (mean size of 82.9 nm) and 
Fig. 8. A typical electrospraying setup presenting isolation of encapsulated drug nanoparticles.  
Table 5 
A summary of API nanoparticles encapsulated into a polymeric matrix using 
electrospraying technique. (DTAB, didodecyl dimethyl ammonium bromide; 
PLGA, Poly(D,L-lactide-co-glycolide); PLA, polylactic acid; PVP, 
polyvinylpyrrolidone).  




















– Chitosan 520 (Arya et al. 
2009) 
Doxorubicin – Elastin-like 
polypeptides 
300–400 (Wu et al. 
2009) 








– Eudragit 80–400 (Garjani 
et al. 
2018) 
Ferulic acid – PVP and 
shellac 
350–900 (Cui et al. 
2014)  
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nanofibres (mean particle size of 232.3 nm) by modulating the drug- 
polymer solution concentration. 
5.2. Multi-step nanoparticle isolation processes 
Nanosuspensions can be stabilized using suitable stabilizers but their 
prolonged storage is associated with chemical instability resulting in 
their hydrolysis, chemical reactivity of the drug, or leakage of the drug. 
Conversion of nanosuspensions to solid nanoparticles can improve the 
physical and chemical stability of nanocrystals (Van Eerdenbrugh et al. 
2008; Bose et al. 2012). Generally, the two-step nanoparticle isolation 
process is used in the pharmaceutical industry to isolate the dry nano-
particle from nanosuspensions. These isolated nanoparticles are either 
coated on the carrier material or encapsulated in the matrix, thus 
improving the physicochemical stability and the rheological properties 
of the nanoparticles. The API nanosuspension is transformed into solid 
products using established isolation approaches namely, drying, filtra-
tion, and coating. The dry powder obtained can be either filled in cap-
sules or compressed into tablets. 
5.2.1. Encapsulating drug nanoparticles using a multi-step isolation process 
The solvent removal techniques that are frequently used in the 
pharmaceutical industries to remove water from nanosuspensions 
include spray drying, freeze drying, electrospraying, vacuum drying, 
oven-drying, and fluidised bed drying. This review article focuses on 
spray drying, freeze drying, and electrospraying; as these techniques can 
efficiently encapsulate drug nanoparticles, as summarised in Table 6. 
5.2.1.1. Encapsulation of drug nanoparticles using a freeze drying process. 
Freeze drying of nanosuspensions to generate dry nanoparticles (as 
presented in Fig. 9) is an established method in the pharmaceutical 
sector. To maintain the primary objective of the nanoparticulate system 
i.e. rapid dissolution, the disintegration of solid forms, and redispersion 
of individual nanoparticles, matrix former is often added to the nano-
suspension (Abdelwahed et al. 2006). The matrix formers used are 
typically water-soluble sugars such as mannitol, sucrose, and lactose, as 
adapted from freeze drying (Kesisoglou et al. 2007). Mauludin et al. 
(Mauludin et al. 2009) freeze dried sodium dodecyl sulfate (SDS) sta-
bilised rutin nanocrystals that were previously produced via a high- 
Table 6 
Summary of drying techniques used to isolate API nanoparticles from nanosuspensions (SDS, sodium dodecyl sulfate; HPMC, hydroxyl propyl methyl cellulose; PVA, 
polyvinyl alcohol; TPGS, D–α–tocopherol polyethylene glycol succinate; PVP, polyvinylpyrrolidone; SDC, sodium deoxycholate; HPC, hydroxyl propyl cellulose; TPP, 





API Stabiliser Nanoparticle size 
(nm) 
Carrier particle Reference 
Freeze drying High-Pressure 
Homogenisation (HPH) 
Rutin SDS or Tween 80 721 – (Mauludin, Müller, and 
Keck 2009) 
Oridonin Pluronic F68 and 
Lecithin 
103.3 ± 1.5 and 
897.2 ± 14.2 
Mannitol (Gao et al. 2008) 
Paclitaxel PSS, GC, SA, and 
Tween 80 
235 and 200 Mannitol (Sharma et al. 2015) 
Bexarotene Poloxamer 188, 
Lecithin, PVP K30 
323.5 ± 12.7 Mannitol (Chen et al. 2014) 
Lutein Decyl glycoside 435 Trehalose (Mitri et al. 2011) 
Ascorbyl 
Palmitate 
Tween 80 365 Trehalose (Teeranachaideekul et al. 
2008) 
Piroxicam Poloxamer 188 501.7 ± 21.1 to 
723.7 ± 14.5 
Xanthan gum, PEG400, and 
maltodextrins 
(Lai et al. 2011) 
Media milling Danazol PVP 400 sucrose (Liversidge, Phillips, and 
Cundy 1994) 
Loviride Tween 80 and 
Poloxamer 188 
264 ± 14 Sucrose (Van Eerdenbrugh et al. 
2007) 
Itraconazole TPGS 337 ± 74 MCC (Sofie et al. 2008) 
Lovastatin HPMC and SDC 503.2 ± 20.4 Mannitol (Guo et al. 2015) 
Naproxen HPC 100–200 Sucrose, lactose, mannitol 
and PEG 
(Lee et al. 2009) 
Ionic gelation Vancomycin TPP 150–650 Glycerol, mannitol, and 
sucrose 
(Cerchiara et al. 2015) 
Sonoprecipitation Lovastatin PVP K30 and Lutrol® 
Poloxamer 188 (F68) 
500.6 ± 21.0 Mannitol and glucose (Guo et al. 2015) 
Antisolvent precipitation Erlotinib SLS 260 ± 4.8 Mannitol, sorbitol, sucrose, 
and trehalose dehydrate 
(Thakkar, Sharma, and 
Misra 2018) 
Electrospraying Doxorubicin – 800 Silk fiber and PVA (Cao et al. 2017) 
Budesonide Tween-20 165 ± 19 to 884 ±
154 
PCL (Midhun et al. 2011) 
Spray drying High-pressure 
homogenisation (HPH) 
Itraconazole Poloxamer 188 and 
SDC 
500 Mannitol (Chaubal and Popescu 
2008) 
Nifedipine HPMC 339 Mannitol (Hecq et al. 2005) 
Cilostazol HPMC 300–1300 Mannitol (Miao et al. 2011) 
Nitrendipine PVA 190 Lactose, mannitol (Quan et al. 2011) 
Media milling Allisartan 
Isoproxil 
SDS 250–550 Mannitol (Hou et al. 2017) 
Candesartan 
cilexetil 
SDS, PVP, Poloxamer 
188 and HPMC 
134 Mannitol (Nekkanti et al. 2009) 
Phenytoin SLS and PVP 630 Mannitol (Niwa, Miura, and Danjo 
2011) 
Antisolvent precipitation Fenofibrate HPMC and SDS 553 Lactose and Mannitol (Hu et al. 2011) 
Fenofibrate SDS 247 Alginate (Hadinoto and Yang 2014) 
Bicalutamide – 330 Lactose, HPMC, arabia gum, 
and MCC 
(Li et al. 2011) 
Electrospraying Antisolvent precipitation Erlotinib SLS 329 ± 5.2 PVA and Mannitol (Thakkar, Sharma, and 
Misra 2018)  
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pressure homogenisation (HPH) process. Nanocrystals of lyophilised 
rutin could be re-dispersed completely in water with an average particle 
size of 721 nm compared to the rutin nanosuspension of average particle 
size of 730 nm. The dissolution velocity of the rutin nanocrystal-loaded 
tablet (100% dissolution in 30 min) was superior compared to rutin 
microcrystal-loaded (71% dissolution) and a marketed tablet (55% 
dissolution). Similarly, Gao et al. (Gao et al. 2008) produced and isolated 
two different sizes (103.3 ± 1.5 nm (suspension A) and 897.2 ± 14.2 nm 
(suspension B) of oridonin nanocrystals prepared using the HPH process, 
using mannitol as the matrix. The dissolution rate of freeze dried sus-
pension A was so fast that 93.2% dissolution was achieved in 5 min, 
while only 35% dissolution was observed for freeze dried suspension B 
particles due to large particle size. Similarly, Tween 80 and low mo-
lecular weight synthetic polymer sodium polystyrene sulfonate (PSS) 
stabilised paclitaxel nanosuspension prepared via the HPH process with 
an average particle size of 235 nm and 200 nm respectively was trans-
formed to dry powder via a lyophilisation process in the presence of 
mannitol. The oral in-vivo pharmacokinetic studies demonstrated that 
paclitaxel nanocrystals exhibit a ~10 fold increase in area under the 
curve (AUC) compared to plain paclitaxel crystals (Sharma et al. 2015). 
Mannitol also formed the matrix for Poloxamer 188 and lecithin stabi-
lised nanosuspension of bexarotene, to achieve an average particle size 
of 323.5 ± 12.7 nm after the freeze drying process (Chen et al. 2014). 
The AUC of bexarotene nanocrystals doubled while the maximum 
saturation concentration (Cmax) was reduced to half, compared to a 
bexarotene nanosuspension indicating a significant increase in the 
bioavailability of bexarotene and also a decrease in undesirable side 
effects. Trehalose has also been successfully used as a matrix former to 
isolate decyl glycoside-stabilised nanosuspensions of lutein (Mitri et al. 
2011) and a Tween 90 stabilised nanosuspension of ascorbyl palmitate 
(Teeranachaideekul et al. 2008). The saturation solubility of lutein 
nanocrystal increased by > 20 fold and permeation through the cellulose 
nitrate membrane was higher (14-fold) compared to the coarse powder. 
Lai et al. (Lai et al. 2011) prepared nanocrystals of piroxicam poly-
morphs using the HPH process and stabilised the nanosuspension using 
Poloxamer 188. Nanocrystals were isolated from the nanosuspension via 
a freeze drying process using Xanthan gum, PEG400 and maltodextrins 
as cryoprotectants. X-ray diffraction confirmed the polymorphic trans-
formation of piroxicam form I to form III and monohydrate, due to high 
energy associated with HPH process. The increased surface to volume 
ratio of piroxicam nanocrystals resulted in the increased dissolution rate 
compared to coarse piroxicam. 
Nanosuspensions produced via media milling, another top-down 
approach, have also been transformed into a solid product using the 
freeze drying method. Liversidge et al. (Liversidge et al. 1994) patented 
the solidification of polyvinylpyrrolidone (PVP) stabilised danazol 
nanosuspension via the freeze drying process using sucrose as the matrix 
former. The average nanocrystal size of the danazol particle was 400 
nm. Sucrose was also used as a cryoprotectant and matrix former for the 
solidification of loviride nanosuspension (mean size of 264 ± 14 nm) 
prepared via a media milling approach using zirconium beads (0.5 mm 
diameter) as a milling agent (Van Eerdenbrugh et al. 2007). The fast- 
dissolving sucrose matrix enabled loviride nanopowder to dissolve 
100% in 15 min compared to 64.7% dissolution of the pure untreated 
loviride at the same time. On the contrary, Sofie et al. (Sofie et al. 2008) 
experienced that a higher amount of sucrose compromised the dissolu-
tion of itraconazole due to agglomeration. Henceforth, they used 
microcrystalline cellulose (MCC) as the matrix former to obtain itraco-
nazole nano powder with faster dissolution. In a related study, Guo et al. 
(Guo et al. 2015) isolated the solid nanospheres (503.2 ± 20.4 nm) of 
lovastatin in the presence of mannitol as the matrix. With the success of 
the use of matrix formers in stabilising and improving the solubility of 
poorly soluble APIs, Lee et al. (Lee et al. 2009) studied the effect of the 
cryoprotectant concentration on the mean size of naproxen nano-
crystals. Different concentrations of sucrose, lactose, mannitol and 
polyethylene glycol (PEG) were studied with the conclusion that a 
higher concentration of all the cryoprotectants and slow freezing rate 
can more effectively protect the nanoparticles. 
Recently, Freeze dying has also been used for the solidification of 
nanosuspensions produced via ionic gelation (Cerchiara et al. 2015), 
sonoprecipitation (Guo et al. 2015), antisolvent precipitation (Thakkar 
et al. 2018), and electrospraying techniques (Cao et al. 2017; Midhun 
et al. 2011). Chitosan-loaded vancomycin nanoparticles were produced 
using ionic gelation techniques which were solidified later using the 
freeze drying process. Sucrose, mannitol, and glycerol were used as 
cryoprotectants with an average particle size of 603.4 ± 70.8 nm, 562.5 
± 71.1 nm, and 187.1 ± 22.3 nm respectively. Despite the smaller 
particle size, the release of vancomycin was poor with only 2% release in 
6 hr (Cerchiara et al. 2015). On the contrary, Guo et al. (Guo et al. 2015) 
isolated nanorods (500.6 ± 21.0 nm) of lovastatin produced via a 
sonoprecipitation technique and stabilised using poloxamer 188 and 
PVP. Lovastatin nanorods exhibited higher dissolution compared to the 
lovastatin nanospheres due to the larger surface area of nanorods 
compared nanospheres. The in-vivo pharmacokinetic study demon-
strated that nanorods were superior to nanospheres. The AUC(0–24h) and 
Cmax of lovastatin for nanorods were about two and three-fold respec-
tively that of marketed lovastatin capsules (Junning®). A different 
approach was used by Thakkar et al. (Thakkar et al. 2018) to produce 
nanocrystals of erlotinib with the aid of sodium lauryl sulfate (SLS) as a 
surfactant in the antisolvent precipitation method. Nanocrystals (260 ±
Fig. 9. Schematic representation of a multi-step approach to encapsulate drug nanoparticles to obtain dry powder using a freeze drying process coupled with top- 
down or bottom-up approaches. 
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4.8 nm) were transformed into solids via a freeze drying process using 
mannitol, sorbitol, sucrose, and trehalose dehydrate as cryoprotectants 
and matrix formers. The physicochemical properties such as particle 
morphology, pore-volume, solid-state, and particle size revealed that the 
lyophilised powder was superior compared to the electrosprayed pow-
der. On the contrary, Cao et al. (Cao et al. 2017) produced a core-shell 
structure with PVA core encapsulating doxorubicin and silk fibroin 
shell with more than 90% encapsulation efficiency using electro-
spraying, which was later freeze dried to obtain a dry powder. The silk 
fibroin coating acted as a barrier limiting the initial burst release of the 
drug. Further, at low pH, silk fibroin lost their overall acidic surface 
properties thus decreasing the electrostatic interactions between doxo-
rubicin and silk fibroin, thereby enabling the release. Similarly, Midhun 
et al. (Midhun et al. 2011) successfully achieved monodisperse nano-
beads of budesonide encapsulated PCL for sustained drug-release ap-
plications. Thus, the above-mentioned literature demonstrates that 
electrospraying coupled with freeze dying is a viable method to generate 
dry powder of a drug entrapped in nanoscale biopolymer matrices. 
5.2.1.2. Encapsulation of drug nanoparticles using the spray drying proc-
ess. Spray drying has been increasingly used as a drying procedure for 
nanosuspension produced by either bottom-up or top-down methods. 
Fig. 10 is a schematic representation of a multi-step approach to 
encapsulate drug nanoparticles to obtain dry powder using the spray 
drying process coupled with top-down or bottom-up approaches. 
Nanosuspension of itraconazole stabilised using poloxamer 188 and 
sodium deoxycholate (SDC) were produced via high-pressure homoge-
nisation (HPH) techniques and transformed into dry powders using 
spray drying. The absence of stabilisers resulted in particle agglomera-
tion thereby limiting the dissolution. Mannitol was added as a matrix 
former, which also provided the most desirable particle morphology and 
enhanced the flowability of the final powder. Spray dried nanoparticles 
dissolved much more rapidly as compared to the micronized drug 
(Chaubal and Popescu 2008). In a related approach, nanosized nifedi-
pine prepared by HPH was spray-dried along with mannitol to isolate a 
solid product (Hecq et al. 2005). The d50 of the re-dispersed spray dried 
particles was 339 nm compared to the 291 nm particle before spray 
drying. Therefore, the carrier particles prevented the nifedipine nano-
particle agglomeration during the spray drying process. Similarly, cil-
ostazol nanocrystals were also isolated as dry solid by spray drying the 
cilostazol nanosuspension in the presence of dissolved mannitol (Miao 
et al. 2011). The saturation solubility of the nanosized cilostazol crys-
talline powder increased by 5-fold, while the dissolution rate was 
enhanced by 4-fold compared to the raw cilostazol powder. In a related 
approach, Quan et al. (Quan et al. 2011) also used mannitol as the matrix 
former to encapsulate nanosized nitrendipine crystalline powder 
(average particle size of 190 nm) by spray drying the nitrendipine 
nanosuspension produced via the HPH process. The in-vivo testing 
demonstrated that the Cmax of the nanocrystals was approximately 15- 
fold and 10-fold greater than that of the physical mixture and com-
mercial tablet, respectively. Besides, the AUC0→24 of the nanocrystals 
was approximately 40-fold and 10-fold greater than that of the physical 
mixture and commercial tablet, respectively. 
Spray drying of media milled nanosuspensions is also a well- 
documented route in the literature to obtain a dry powder. Dry nano-
particles of allisartan isoproxil were produced by spray drying the media 
milled nanosuspension of allisartan isoproxil. The optimised formula-
tion gave a drug loading of 61.7% and high redispersity. It was also 
observed that the nanocrystal size of the re-dispersed formulation de-
creases with increasing stabiliser concentration. In addition, the 
bioavailability of the optimal formulation increased by 4.73 times 
compared to the crude drug (Hou et al. 2017). Similarly, a milled 
nanosuspension of candesartan cilexetil nanoparticles produced using a 
wet bead milling technique was converted to a solid intermediate via a 
spray drying process. The redispersity of the spray dried particles was 
high with an average particle size of 134 nm compared to the nano-
suspension size of 127 nm. Tablets prepared using spray dried drug 
nanoparticles of candesartan cilexetil presented significantly higher 
dissolution compared to its micronized and commercial formulations. 
Systemic exposure studies in rats indicated a significant increase in the 
rate and extent of drug absorption with a 2.51-fold increase in area 
under the curve (AUC0-t) and a 1.77-fold increase in the plasma con-
centration (Nekkanti et al. 2009). With the success of mannitol as a 
matrix former in freeze drying processes, Niwa et al. (Niwa et al. 2011) 
used it to encapsulate dry nanoparticles of phenytoin produced via the 
milling process. The dried nanosuspension of the phenytoin product 
could be spontaneously redispersed in water, transforming into a 
nanosuspension, and displayed immediate release behaviour in both 
acidic and neutral media. 
The spray drying process can also be used with nanosuspension 
produced by the antisolvent precipitation method (Thakkar et al. 2018; 
Hu et al. 2011; Hadinoto and Yang 2014; Li et al. 2011). A dry powder of 
fenofibrate nanoparticles (553 nm) was produced by immediately spray 
drying the nanosuspension. Particle growth and aggregation were 
minimised by adding lactose or mannitol as re-dispersant, and hydrox-
ypropyl methylcellulose (HPMC) and sodium dodecyl sulfate (SDS) as 
stabilizers. The spray dried nanoformulation quickly disintegrates into 
nanosized fenofibrate upon reconstitution in water and exhibited a 
significantly higher drug dissolution rate 84.2% compared to the phys-
ical mixture (31.7%) within 5 min (Hu et al. 2011). In a different 
approach, SDS stabilised fenofibrate nanoparticles were encapsulated by 
spray coagulation in alginate by Hadinoto and Yang (Hadinoto and Yang 
2014) The process exhibited a high production yield of 81 ± 17% (w/w), 
which is higher than the yield achievable in the conventional NP 
Fig. 10. Schematic representation of a multi-step approach to encapsulate drug nanoparticles to obtain dry powder using the spray drying process coupled with top- 
down or bottom-up approaches. 
V. Verma et al.                                                                                                                                                                                                                                  
International Journal of Pharmaceutics 603 (2021) 120708
15
granulation method via spray drying (around 40%). It also showed a 
Carr’s index of 37 ± 2, exhibiting good flowability. The granules also 
readily compacted into tablets, therefore further enhancing the sus-
tainability of the overall oral solid dosage form preparation. Similarly, Li 
et al. (Li et al. 2011) produced lactose-loaded bicalutamide nano-
particles with an average size of 330 nm and narrow size distribution via 
a combination of antisolvent precipitation and spray drying methods. 
The lactose–bicalutamide formulation achieved a 2-fold increase in the 
dissolution rate in 10 min compared to the commercial bicalutamide 
tablets. Further, the antisolvent precipitation approach was combined 
with the electrospraying process to produce mannitol-loaded erlotinib 
nanocrystal stabilised using sodium lauryl sulfate (SLS). The particle 
size, surface area, pore-volume, and % drug release for the re-dispersed 
nanocrystals were 329 ± 5.2 nm, 0.341 ± 0.05 m2/g, 0.0009 cc/g, and 
~78% in 600 min respectively (Thakkar et al. 2018). Therefore, 
coupling antisolvent precipitation with a spray drying process has huge 
potential to achieve continuous industrial-scale production of pharma-
ceutical nanoformulations. 
5.2.2. Coating drug nanoparticles onto carrier particles using a multi-step 
isolation process 
The multi-particulate drug delivery system such as API coated onto 
microparticles/pellets offer many advantages in comparison to single- 
unit dosage forms, for example, uniform drug dispersion in the gastro-
intestinal (GI) tract leading to minimal variability in the bioavailability 
(Schmidt and Bodmeier 2001) and more predictable gastric emptying 
(Efentakis et al. 2000). The combination of the mucoadhesion principle 
and nanonisation of the drugs is an effective dosage form with enhanced 
efficiency (Kayser 2001). Mucoadhesion is commonly defined as the 
adhesion between the two materials. The materials adhere because of 
the forces acting between two chemical structures which could be either 
physisorption or chemisorption based on the interaction (Shaikh et al. 
2011). The mucoadhesive polymers possess numerous hydrophilic 
groups such as hydroxyl, amide, carboxyl, and sulfate, which leads to the 
adhesion of pharmaceutical drugs. Among all the nanocrystal-based 
drugs on the market, only Emend® by Merck is a multi-particulate 
dosage form containing drug nanocrystals. 
5.2.2.1. Coating drug nanoparticles onto dry carrier particles using a flui-
dised bed process. Fig. 11 is a schematic representation of a multi-step 
approach to coat carrier particles with drug nanoparticles to obtain a 
dry powder using a fluidised bed process coupled with top-down or 
bottom-up approaches. Literature discussing the coating of drug nano-
particles onto carrier particles using a fluidised bed process in a multi- 
step process is summarised in Table 7. Vergote et al. (Vergote et al. 
2001) were the first to discuss the incorporation of nanocrystalline 
ketoprofen as a spray dried powder into controlled release matrix pel-
lets. Later on, other researchers also used the mucoadhesion principle to 
coat drug nanocrystals onto sugar and cellulose-based excipient parti-
cles. Nanosizing of the drug particles is achieved by either top-down or 
bottom-up approaches while adhesion to the excipient is controlled by 
the fluidised bed process. Nanocrystals of hydrocortisone acetate (908 
± 3 nm) produced using high-pressure homogenisation (HPH) process 
and stabilised using poloxamer 188 and chitosan chloride were coated 
onto sugar beads (710–850 µm) via a fluidised bed process equipped 
with a Wurster column and bottom spray nozzle (Moschwitzer and 
Muller 2006). Drug release could be tailored according to the pH by 
applying an enteric coating on the nanocrystal sugar beads. Similarly, 
Bourezg et al. (Bourezg et al. 2012) successfully coated nanoparticles of 
Stearoyl macrogol-32 glycerides (SMG) and Glyceryl dibehenate (GB) 
lipids containing dissolved spironolactone onto sorbitol and mannitol 
carrier particles. The particle size of SMG and GB nanosuspension was 
82.7 nm and 254.6 nm respectively. After the successful fluidisation 
process, the coating efficiency and drying yield of SMG and GB nano-
particles were (93.54% and 56.6%), and (98.37% and 86.7%) respec-
tively. The coating process enhanced the dissolution and stability 
properties of spirolnolactone. Therefore, it was shown that a fluidised 
process is an ideal technique to produce granules but is also time- 
consuming and requires prolonged high temperatures that may also 
lead to product degradation. 
In another approach, a fluidized bed pellet coater with a Wurster 
insert was used to coat the naproxen and cinnarizine nanosuspensions 
prepared by media milling on sugar beads (710–850 µm) (Kayaert et al. 
2011). Coating of cinnarizine nanosuspensions resulted in complete 
dissolution in 15 min, compared to only 11% in 1 h for the unmilled 
powder. Naproxen also dissolved three times faster when formulated on 
Fig. 11. Schematic representation of multi-step approach to coat carrier particles with drug nanoparticles to obtain dry powder using fluidised bed process coupled 
with top-down or bottom-up approaches. 
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a bead. Cinnarizine showed re-agglomeration upon release from the 
coating, limiting the dissolution behaviour which was solved by using a 
higher stabiliser concentration. Hence, a higher concentration of stabi-
liser may be required to keep the drug nanocrystals dispersed in the 
dissolution medium even if that concentration is not required to stabilise 
the nanosuspension (Kayaert et al. 2011). Similarly, an itraconazole 
nanosuspension was coated onto sugar beads (1000–1400 µm & 
177–250 µm) & cellulose spheres (1000–1400 µm & 210–355 µm). 
HPMC was used as a coating polymer while PEG 400, was used as a 
plasticiser dissolved with the itraconazole nanosuspension to avoid 
agglomeration of the itraconazole nanocrystals, for immediate release 
(Parmentier et al. 2017). The itraconazole layered beads were mixed 
with another excipient, microcrystalline cellulose (MCC) to access the 
tabletability of the layered beads. The compressed tablets presented 
adequate tensile strength and a fast dissolution rate with a release of 
99.0% (±1.0% SD) within 10 min. Hence, the compaction of 
nanosuspension-layered beads is a suitable process for processing an 
itraconazole nanosuspension into a solid dosage form, such as a com-
pacted tablet, without compromising on drug release (Tan et al. 2017). 
Basa et al. (Basa et al. 2008) prepared a ketoconazole nanosuspension 
using a media-milling technique, which was layered onto the water- 
soluble carrier (lactose monohydrate) using a fluid bed processor to 
obtain a ketoconazole nanoparticle formulation with enhanced 
bioavailability and proper systemic exposure. The tablets compressed 
with nanosuspension-layered carrier particles presented < 0.1% fria-
bility indicating good mechanical strength. The rate and extent of drug 
dissolution from tablets incorporating ketoconazole nanoparticles was 
significantly higher, 65% as compared with 45% for micronized and 
37% for commercial formulation at the end of 60 min. Besides, there 
were no impact on the tablet dissolution upon storage for three months 
at accelerated (40 ◦C/75% RH) and room temperature conditions 
(25 ◦C/60% RH). Similarly, lactose monohydrate was also used as car-
rier particles to prepare dispersible fast-dissolving dry nanocomposite 
microparticles with high drug loading (40–49%) of azodicarbonamide 
nanocrystals (Bhakay et al. 2014). 
In a similar approach, core-shell nanocomposites of fenofibrate and 
itraconazole were prepared for a well-stabilised high drug-loaded 
nanosuspension using a fluidised bed coating process (Azad et al. 
2016). Both fine carrier particles (GranuLac® 200 (<50 µm)) and large 
carrier particles (PrismaLac® 40 (>300 µm)) were used for the coating 
process. The resulting fine carrier particles were freely flowing, had high 
bulk density, and had much faster, immediate dissolution of the poorly 
water-soluble drugs, in particular for itraconazole. This is attributed to a 
much higher specific surface area of the carrier and corresponding 
thinner coating layer for fine carriers as opposed to those for large 
carrier particles (Azad et al. 2016). Similarly, Figueroa et al. (Figueroa 
and Bose 2013) converted naproxen and a proprietary Novartis com-
pound into nanosuspensions through wet media milling and successfully 
spray dried onto mannitol (150 µm). In-vivo studies in beagle dogs with 
the proprietary Novartis compound showed no significant difference 
between the liquid and the dried forms of the nanosuspension in terms of 
overall area under the curve (AUC). However, differences were observed 
in the maximum time (tmax) which correlated with the rank ordering 
observed from the in vitro dissolution profiles. This makes spray gran-
ulation an eye-catching option for the production of powders with 
desired processing and handling properties without compromising the 
enhanced pharmacokinetic profiles of the active compound in nano-
particle form. The same group also used another proprietary Novartis 
compound and converted its nanosuspension into a solid dosage form 
using a spray granulation process. Granulation with 10% drug loading 
resulted in a dissolution rate similar to the nanosuspension while the 
dissolution rate was compromised with 20% drug loading due to particle 
agglomeration. An in-vivo pharmacokinetic study in beagle dogs showed 
an 8-fold increase and a 6-fold increase in the AUC0–48 from the nano-
suspension and dried nanosuspension formulations respectively 
compared to the coarse suspension. Also, the nanosuspension and dried 
nanosuspension formulations showed a 12-fold and 8-fold increase in 
the maximum concentration (Cmax) respectively compared to the coarse 
suspension (Bose et al. 2012). 
In a different approach, Horster et al. (Horster et al. 2019) produced 
poly(DL-lactide-co-glycolide) (PLGA) nanosuspension using the elec-
trospraying process which was later converted into the solid product 
using a fluidised bed coating technique with lactose (40–100 µm) and 
microcrystalline cellulose (100–150 µm) as the carrier particles. Fluid 
bed granulation with aqueous PLGA nanoparticle suspensions and sol-
uble carriers was shown to be a simple and high yield process for drying 
the nanoparticles. The granules were compressed to tablets without 
impairing the nanoparticle diameter and the highest nanoparticle 
release was achieved in the presence of comparable high amounts of the 
filler MCC in combination with a low tablet breaking strength. 
5.2.2.2. Coating drug nanoparticles onto insoluble carrier particles. In the 
last decade, researchers have been able to successfully produce nano-
suspensions with several different active ingredients. By controlling the 
Table 7 
Coating of drug nanoparticles onto carrier particles using fluidised bed process in a multi-step process. The nanosuspension of drug nanoparticles was generated either 
by high-pressure homogenisation, media milling, or emulsion diffusion. (SMP, sucrose mono palmitate; TPGS, D–α–tocopherol polyethylene glycol succinate; SDS, 
sodium dodecyl sulfate; HPMC, hydroxyl propyl methyl cellulose; SLS; sodium lauryl sulfate; HPC, hydroxyl propyl cellulose; PLGA, poly(lactic-co-glycolic acid); PVA, 
polyvinyl alcohol).  
Nanosuspension 
technique 
API Stabilisers Nanoparticle 
size (nm) 




Hydrocortisone acetate Poloxamer 188 and 
chitosan chloride 
908 ± 3 Sugar beads (710–850 µm) (Moschwitzer and 
Muller 2006) 
Spironolactone Poloxamer 188, SMP 50–250 Sorbitol & Mannitol (Bourezg et al. 2012) 
Media milling Naproxen & Cinnarizine TPGS and 
hypermellose 
380 and 410 Sugar beads (710–850 µm) (Kayaert, Anne, and 
Van den Mooter 2011) 
Itraconazole SDS and HPMC E5 200 Sugar beads (1000–1400 µm & 177–250 µm) 
& Cellulose sphere (1000–1400 µm & 
210–355 µm) 
(Tan et al. 2017; 
Parmentier et al. 2017) 
Ketoconazole SLS and HPMC 150–250 Lactose monohydrate (Basa et al. 2008) 
Azodicarbonamide SDS and HPC 250 Lactose monohydrate (Bhakay et al. 2014) 
Fenofibrate & Itraconazole SDS and HPMC 200 GranuLac® 200 (<50 µm) & PrismaLac® 40 
(>300 µm) 
(Azad et al. 2016) 
Proprietary Novartis 
compound 
TPGS and HPMC 200–400 Mannitol (150 µm) & Spray dried lactose 
monohydrate (150 µm) 
(Bose et al. 2012) 
Naproxen & Proprietary 
Novartis compound 
SLS and HPMC 300 Mannitol (150 µm) (Figueroa and Bose 
2013) 
Emulsion diffusion PLGA PVA 198 ± 5 Lactose (40–100 µm) & Microcrystalline 
cellulose (100–150 µm) 
(Horster et al. 2019)  
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rate of nucleation and growth and by employing rapid mixing, a narrow 
particle size distribution of particles can be achieved particularly in the 
nano range. Some of the above sections extensively described the pro-
cesses for generating and isolating nanoparticles. The main bottleneck 
associated with nanoparticles is stabilisation due to their small size 
thereby leading to higher surface area but reduced stability (Tierney 
et al. 2017; Kumar et al. 2019; Kumar et al. 2020). Hence, to preserve the 
small particle size of the individual nanoparticles, certain stabilizers are 
used to control the growth of preformed nanoparticles. Stabilisers can be 
classified as non-ionic polymers (eg: polyvinyl alcohol (PVA), polyvinyl 
pyrrolidone (PVP), polyethylene glycol, cellulose, and its derivatives, 
etc.), anionic polymers (eg: phosphates, albumins, alginates, etc.), 
cationic polymers (eg: chitosan and its derivatives, etc.), surfactants (eg: 
tween, span, phospholipids, etc.) (Wu et al. 2011). Stabilisers mainly 
wet the nanoparticles by adsorbing on the particle at a specific 
adsorption site thereby preventing Ostwald ripening and agglomeration 
of nanoparticles. This adsorption disrupts the interaction with the 
adjacent nanoparticle and thus eliminating crystal growth. Adsorption 
of the additive on the nanoparticles is facilitated either by non-covalent 
interactions such as hydrogen bonding, hydrophobic/hydrophilic 
interaction, or by electrostatic/ionic interactions (Van Eerdenbrugh 
et al. 2008; Liu 2013). 
For long-term stabilization and convenience during oral adminis-
tration, drug nanoparticles are often isolated into the solid state for 
incorporation into solid dosage forms such as tablets. Nanoparticle 
isolation methodologies as described above-comprising solvent evapo-
ration techniques such as spray drying, freeze drying, and electro-
spraying, or coating techniques such as fluidised bed coating process. 
Though these techniques can isolate drug particles in their nano form, 
they can also be at times consuming, expensive, difficult to scale up, and 
can adversely affect the particle size (Chaubal and Popescu 2008; Mat-
teucci et al. 2006; Abdelwahed et al. 2006). In 2014 Khan et al. (Khan 
et al. 2014) published the first report to isolate pharmaceutical nano-
crystals using an insoluble carrier. They successfully produced the 
nanosuspension of ibuprofen and glibenclamide using the antisolvent 
precipitation process and then used dibasic calcium phosphate as an 
insoluble carrier particle to isolate the drug nanocrystals using the 
filtration approach. However, the process was notably limited by a low 
maximum drug loading of 0.35%, restricting its application to high 
potency drugs. A schematic of the production and isolation of API 
nanoparticles using insoluble carrier particles is presented in Fig. 12. 
Filtration techniques have been largely used in the pharmaceutical 
industry, but can be problematic when dealing with sub-micron or nano- 
sized particles. Hence the adsorption/adhesion of nanoparticles to mi-
croparticles can facilitate the filtration of drug nanoparticles. As dis-
cussed earlier, the coating of drug nanoparticles onto 1–5 µm 
microparticles facilitates the pulmonary delivery systems by preparing 
effective dry powder inhaler formulations with improved rheological 
properties of nanoparticles (Smyth and Hickey 2005; Frijlink and De 
Boer 2004). Therefore, the adsorption /adhesion of drug nanoparticles 
to the surface of a carrier particle with a subsequent filtration step could 
be an efficient way to isolate drug nanoparticles with improved rheo-
logical properties. 
Table 8 summarises the nanocrystals isolated from nanosuspensions 
using insoluble carrier particles. After the isolation of ibuprofen and 
glibenclamide using dicalcium phosphate by Khan et al. (Khan et al. 
2014), other researchers also used a similar approach to isolate other 
drug nanoparticles with increased loading. Tierney et al. (Tierney et al. 
2017) used protamine-modified montmorillonite (MMT) clay as carrier 
particles to isolate nanoparticles of BCS class II drugs, fenofibrate, and 
mefenamic acid with a maximum loading of 9.1% and 4.8% respectively 
with significantly improved dissolution. Protamine was used as a charge 
modifier, to modify the charges on the MMT surface to achieve a uni-
form coating of drugs. Protamine modification of MMT not only 
increased the fenofibrate loading onto the MMT surface from 4.8% to 
9.1% but also increased the speed of filtration. The filtration speed of the 
fenofibrate system increased by 10-fold while 6-fold for the mefenamic 
acid system, compared to non-modified MMT. Hence, Tierney et al. 
(Tierney et al. 2017) developed a novel one-step, carrier-mediated 
method for preparing, stabilising, and isolating fast-dissolving, solid- 
state drug nanoparticles of poorly water-soluble BCS Class II drugs with 
increased drug loading. Later on, the same group extended the study to 
isolate nanoparticles of curcumin, clozapine base, and valsartan (Kumar 
et al. 2019) with enhanced loading of 21.8%, 28%, and 33.3% respec-
tively using protamine modified MMT as a carrier (Kumar et al. 2020). 
Fig. 8 provides a schematic path to produce and isolate valsartan 
nanoparticles from the nanosuspension using MMT or protamine 
modified MMT as carrier particles. Further, they also isolated dalce-
trapib (Bodnár et al. 2020) and carbamazepine (Kumar et al. 2020) 
nanoparticles with a higher drug loading of 20.9% and 33.3% without 
modifying MMT with protamine. The Hudson research group founded a 
correlation between the zeta potential of API nanoparticles and the 
surface properties of the carrier particles to obtain high drug loading 
onto carrier particles. They concluded that the API nanoparticles with 
zeta potentials more negative than ca. − 25 mV require a carrier particle 
surface modified with protamine to obtain a uniform coating of nano-
particles onto the carrier surface and to maintain the fast dissolution 
from nanoparticle-carrier composite at higher API loadings (Kumar et al. 
2020). Hence, this nanoparticle generation and isolation process pro-
vides huge potential to produce a fast dissolving solid dosage form of 
poorly soluble APIs. 
Fig. 12. Schematic of the production and isolation of API nanoparticles using insoluble carrier particles.  
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6. Conclusions and future perspective 
The goal of this review is to provide a summary of existing tech-
nologies to produce and isolate dry nanoparticles. A range of different 
one-step and multi-step techniques has been shown effective to generate 
and stabilise nanoparticles of pharmaceutical drugs. The isolation of 
nanocrystals has been achieved by either coating or encapsulation with 
the aid of GRAS (generally regarded as safe) approved carriers or matrix 
materials. The nanocrystal isolation approaches developed largely 
ignore the processing steps of granulation, bead layering, and tabletting. 
Further research is needed to deepen our understanding of the down-
stream processing of isolated drug nanocrystals, which can greatly in-
fluence the contribution to the future application of drug nanocrystals 
for oral delivery purposes. 
Nanosizing means achieving a particle size < 1 µm (Junyaprasert and 
Morakul 2015). It is well understood in the literature that a decrease in 
the particle size of drugs increases its surface area and thus propor-
tionally an increase in the dissolution rate and the saturation solubility. 
Drug nanocrystals with increased dissolution also improve the 
bioavailability and pharmacokinetic properties of poorly soluble drugs 
that are administered through various administration routes such as 
oral, ocular, dermal, pulmonary, and buccal (Al-Kassas et al. 2017). In 
addition to improving solubility, nanocrystal formulations also offer 
decreased toxicity and increased efficacy because of passive and active 
targeting (Allen and Cullis 2004). 
Nanosuspension technology has offered a viable approach to 
formulate poorly soluble drugs with increased bioavailability leading to 
a decrease in the dose and subject-to-subject variability. However, due 
to the potential risk of physical instability (such as agglomeration and 
Ostwald ripening) and chemical instabilities (such as hydrolysis and 
oxidation), liquid nanosuspension is converted to solid dosage forms 
such as tablets, capsules, pellets, and granules. This further improves the 
sampling and handling of the produced nanopowders, which are 
particularly challenging downstream issues. While the nanocrystal 
technology is attractive due to ease of formulation and macroeconomic 
values, it also has the potential to overcome the biggest challenges of 
drug development. The factors influencing the clinical efficacy of 
nanocrystal drugs include size, morphology, surface charge, degree of 
redispersability, and site-specific targeting. Therefore, meticulously 
studying the above-mentioned factors will enable nanocrystal drugs to 
open up new frontiers in the field of therapeutics. Developing crystalline 
products with a size below 100 nm will provide an add-on advantage 
towards avoiding renal clearance and sequestration by the mononuclear 
phagocytic system. Thus, nanocrystals bear the potential to become a 
benchmark therapeutic platform for cancer and other diseases. In 
addition, the ability to develop nanocrystal products of the off-patent 
drugs for clinical use will provide a competitive edge for pharmaceu-
tical companies in the market. 
Despite the impressive methods and nanosizing technologies avail-
able to the pharmaceutical industries, only a few formulations con-
taining drug nanocrystals have been able to reach clinical trial phases or 
even be approved by regulatory agencies. One of the many reasons is 
that the nanosizing principle is a complex process in comparison to 
providing simple pre-clinical formulations, and many pharmaceutical 
companies lack sufficient in-house capabilities in terms of technology 
and expertise to develop nanocrystals for clinical studies. Typically, 
nanosizing of poorly soluble APIs needs to be outsourced to specialised 
contractors, who often own IP on the production technology and have 
the necessary know-how in the manufacture of such nanoformulations. 
The other reason is that nanosized formulations have to compete with 
products of other enabling technologies that can be easily produced 
using in-house facilities that are already established (Müller and Keck 
2012). Other reasons are linked to poor rheological properties of 
nanoformulations that still need to be addressed to design novel nano-
medicines (Bobo et al. 2016). This could potentially be managed by a 
synergistic interaction and communication between researchers with 
different backgrounds. 
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Li, Meng, Azad, Mohammad, Davé, Rajesh, Bilgili, Ecevit, 2016. Nanomilling of Drugs for 
Bioavailability Enhancement: A Holistic Formulation-Process Perspective. 
Pharmaceutics 8, 17. 
Li, Q., Huang, D., Lu, T., Seville, J.P.K., Xing, L., Leeke, G.A., 2017. Supercritical fluid 
coating of API on excipient enhances drug release. Chem. Eng. J. 313, 317–327. 
Chin, Lim, Wei, William, Parmentier, Johannes, Widzinski, Michael, Tan, En Hui, 
Gokhale, Rajeev, 2014. A Brief Literature and Patent Review of Nanosuspensions to a 
Final Drug Product. J. Pharm. Sci. 103, 2980–2999. 
Limayem Blouza, I., Charcosset, C., Sfar, S., Fessi, H., 2006. Preparation and 
characterization of spironolactone-loaded nanocapsules for paediatric use. Int. J. 
Pharm. 325, 124–131. 
Limayem, Imène, Charcosset, Catherine, Fessi, Hatem, 2004. Purification of nanoparticle 
suspensions by a concentration/diafiltration process. Sep. Purif. Technol. 38, 1–9. 
Liu, Peng, 2013. Nanocrystal formulation for poorly soluble drugs. 
Liversidge, Gary G, Christopher P Phillips, and Kenneth C Cundy, 1994. Method to 
reduce particle size growth during lyophilization. In.: Google Patents. 
Liversidge, Gary G., Cundy, Kenneth C., Bishop, John F., Czekai, David A., 1992. Surface 
modified drug nanoparticles. Sterling Drug Inc. 
Long, B., Ryan, K.M., Padrela, L., 2019a. From batch to continuous — New opportunities 
for supercritical CO2 technology in pharmaceutical manufacturing. Eur. J. Pharm. 
Sci. 137, 104971. 
V. Verma et al.                                                                                                                                                                                                                                  
International Journal of Pharmaceutics 603 (2021) 120708
21
Long, B., Walker, G.M., Ryan, K.M., Padrela, L., 2019b. Controlling Polymorphism of 
Carbamazepine Nanoparticles in a Continuous Supercritical-CO2-Assisted Spray 
Drying Process. Cryst. Growth Des. 19, 3755–3767. 
Louey, Margaret D., Van Oort, Michiel, Hickey, Anthony J., 2004. Aerosol Dispersion of 
Respirable Particles in Narrow Size Distributions Produced by Jet-Milling and Spray- 
Drying Techniques. Pharm. Res. 21, 1200–1206. 
Mark, J.E., 2009. Polymer Data Handbook (Oxford University Press). 
Matos, R.L., Lu, T., Leeke, G., Prosapio, V., McConville, C., Ingram, A., 2020. Single-step 
coprecipitation and coating to prepare curcumin formulations by supercritical fluid 
technology. J. Supercrit. Fluids 159, 104758. 
Matos, R.L., Lu, T., McConville, C., Leeke, G., Ingram, A., 2018. Analysis of curcumin 
precipitation and coating on lactose by the integrated supercritical antisolvent- 
fluidized bed process. J. Supercrit. Fluids 141, 143–156. 
Matson, Dean W., Fulton, John L., Petersen, Robert C., Smith, Richard D., 1987. Rapid 
expansion of supercritical fluid solutions: solute formation of powders, thin films, 
and fibers. Ind. Eng. Chem. Res. 26, 2298–2306. 
Matson, Dean W., Petersen, Robert C., Smith, Richard D., 1986. The preparation of 
polycarbosilane powders and fibers during rapid expansion of supercritical fluid 
solutions. Mater. Lett. 4, 429–432. 
Matteucci, Michal E., Hotze, Margaret A., Johnston, Keith P., Williams, Robert O., 2006. 
Drug Nanoparticles by Antisolvent Precipitation: Mixing Energy versus Surfactant 
Stabilization. Langmuir 22, 8951–8959. 
Mauludin, Rachmat, Müller, Rainer H., Keck, Cornelia M., 2009. Development of an oral 
rutin nanocrystal formulation. Int. J. Pharm. 370, 202–209. 
Merisko-Liversidge, Elaine, Liversidge, Gary G., 2011. Nanosizing for oral and parenteral 
drug delivery: A perspective on formulating poorly-water soluble compounds using 
wet media milling technology. Adv. Drug Deliv. Rev. 63, 427–440. 
Miao, X., Sun, C., Jiang, T., Zheng, L., Wang, T., Wang, S., 2011. Investigation of 
nanosized crystalline form to improve the oral bioavailability of poorly water soluble 
cilostazol. J. Pharm. Pharm. Sci. 14, 196–214. 
Midhun, B.T., Shalumon, K.T., Manzoor, K., Jayakumar, R., Nair, S.V., Deepthy, M., 
2011. Preparation of budesonide-loaded polycaprolactone nanobeads by 
electrospraying for controlled drug release. J. Biomater. Sci. Polym. Ed. 22, 
2431–2444. 
Mitri, Khalil, Shegokar, Ranjita, Gohla, Sven, Anselmi, Cecilia, Müller, Rainer H., 2011. 
Lutein nanocrystals as antioxidant formulation for oral and dermal delivery. Int. J. 
Pharm. 420, 141–146. 
Moschwitzer, J., Muller, R.H., 2006. Spray coated pellets as carrier system for 
mucoadhesive drug nanocrystals. Eur. J. Pharm. Biopharm. 62, 282–287. 
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